Defining the Optimal Cryoballoon Duration Therapy for Treatment of Atrial Fibrillation: Defining the Optimal Cryoballoon Duration Therapy for Treatment of Atrial Fibrillation: The 1-2-3 Study

Defining the Optimal Cryoballoon Duration Therapy for Treatment of Atrial Fibrillation: Defining the Optimal Cryoballoon Duration Therapy for Treatment of Atrial Fibrillation: The 1-2-3 Study

A Prospective Randomized Multicentre Efficacy Study on Defining the Optimal Cryoballoon Duration Therapy for Treatment of Atrial Fibrillation: The 1-2-3 Study

Cryoballoon based therapy is an established therapy for the treatment of (paroxysmal) atrial fibrillation. However, with the rapid evolution in cryoablation technique and its increased effectiveness, the risk of complications increases. Therefore it is of utmost importance to define the optimal duration of cryoballoon ablation time.The objective of the study is to assess the optimal ablation duration using the second generation cryoballoon for isolation of pulmonary veins in the treatment of atrial fibrillation.

Rationale Cryoballoon based therapy is an established therapy for the treatment of (paroxysmal) atrial fibrillation. However, with the rapid evolution in cryoablation technique and its increased effectiveness, the risk of complications increases. Therefore it is of utmost importance to define the optimal duration of cryoballoon ablation time. Objective To assess the optimal ablation duration using the second generation cryoballoon for isolation of pulmonary veins in the treatment of atrial fibrillation. Study design The study is designed as a prospective multicentre randomized efficacy study. Study population Patients 18-70 years of age with paroxysmal atrial fibrillation eligible for pulmonary vein isolation according to current international guidelines. Intervention Patients will be randomized to 2 cycles of 1, 2 or 3 minutes of cryoballoon ablation after reaching the temperature "plateau phase". Main study parameters/endpoints Acute success of pulmonary vein isolation. Nature and extent of the burden and risks associated with participation, benefit and group relatedness: No additional risk is present as the procedure is common clinical practice, current cryoballoon application time is 3 minutes Shorter application times are not expected to add to the risk.

Assessment of successfull pulmonary vein isolation after 2 x 1/2/3 minutes of cryoballoon application. The assessment of this outcome will take place during the procedure.

Complications being: Phrenic nerve palsy or diminishment of diaphragm excursion during cryo-ablation. Temperatures reaching <12 C in the oesophagus during cryoablation. Other complications such as delayed gastric emptying, pericardial fluid/tamponade, haemoptoe, vascular complications.

Duration of thaw phase (= time between end of freezing to automatic deflation of the balloon) related to acute success of pulmonary vein isolation

The assessment of this outcome will take place right after the procedure. It measures procedural parameters.

The measurement will take place during the procedure. It registrates the lower esophageal temperature ande the development during the course of the procedure.

Inclusion Criteria: Paroxysmal atrial fibrillation eligible for pulmonary vein isolation according to current international guidelines. Age < 70 years. Willing and able to sign informed consent. Willing to and capable of following the requested study procedures. Exclusion Criteria: Age < 18 years. Pregnancy Life or follow-up expectancy < 12 months. Previous PVI. Contrast allergy. Creatin clearance level < 60. Left ventricular ejection fraction < 40% Abnormal left atrium anatomy defined as number of PV's ≠ 4 or Left Atrium diameter >50mm (measured in the parasternal long axis, as assessed with transthoracic echocardiography) or >40 cc/m2 . This will lead to exclusion after inclusion but before randomisation.